Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.54 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6825084 | 0.92 | CYP2D6 (0.49) | CYP2D6CYP2C9CYP2C19ALDH1A1MAPT | |
| Toluene SCHEMBL28291699 | 0.85 | HPGD (0.48) | CYP2D6CYP2C9CYP2C19ALDH1A1MAPT | |
| SCHEMBL1164889 | 0.78 | CYP2D6 (0.62) | CYP2D6CYP2C9CYP2C19ALDH1A1MAPT | |
| SCHEMBL24254325 | 0.77 | CYP2D6 (0.67) | CYP2D6CYP2C9CYP2C19ALDH1A1MAPT | |
| SCHEMBL30517142 | 0.75 | CYP2D6 (0.50) | CYP2D6CYP2C9CYP2C19ALDH1A1MAPT | |
| SCHEMBL1863910 | 0.74 | CYP2D6 (0.62) | CYP2D6CYP2C9CYP2C19ALDH1A1MAPT | |
| SCHEMBL8232303 | 0.74 | CYP2D6 (0.62) | CYP2D6CYP2C9CYP2C19ALDH1A1MAPT | |
| SCHEMBL4433902 | 0.74 | CYP2D6 (0.62) | CYP2D6CYP2C9CYP2C19ALDH1A1MAPT | |
| SCHEMBL7455235 | 0.74 | CYP2D6 (0.62) | CYP2D6CYP2C9CYP2C19ALDH1A1MAPT | |
| SCHEMBL855231 | 0.74 | L3MBTL1 (0.56) | CYP2D6CYP2C9CYP2C19ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119447465-A | Electrolyte and application thereof in double-ion battery | 广西师范大学 | 2025-02-14 | — | — | CN | claimed |
| CN-121885770-A | Lithium ion battery and power utilization device | 深圳市豪鹏科技股份有限公司 | 2026-04-17 | — | — | CN | disclosed |
| CN-119447465-A | Electrolyte and application thereof in double-ion battery | 广西师范大学 | 2025-02-14 | — | — | CN | disclosed |
| CN-116487696-A | Nonaqueous electrolyte, lithium ion battery, battery module, battery pack, and power utilization device | 上海如鲲新材料股份有限公司 | 2023-07-25 | — | — | CN | disclosed |
| US-20210024498-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | MEDICONNS SHANGHAI BIOPHARMACEUTICAL CO LTD (CN) | 2021-01-28 | — | — | US | disclosed |
| CN-109715615-A | Biaryl methyl heterocycles | 蒙特利尔大学 | 2019-05-03 | — | — | CN | disclosed |
| US-9422271-B2 | Pyrimidine compounds as tuberculosis inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-23 | — | — | US | disclosed |
| EP-1869009-B1 | NEW BICYCLIC ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2016-06-01 | — | — | EP | disclosed |
| US-9139609-B2 | C-4″ position substituted macrolide derivative | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-22 | — | — | US | disclosed |
| US-20140249137-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-04 | — | — | US | disclosed |
| US-5585377-A | CONTROLLING INTRAOCULAR PRESSURE | ALCON LABORATORIES, INC. (US) | 1996-12-17 | — | — | US | disclosed |
| US-5444067-A | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety | MERCK & CO., INC. (US) | 1995-08-22 | — | — | US | disclosed |
| US-5378703-A | FOR CONTROLLING INTRAOCULAR PRESSURE | ALCON LABORATORIES, INC. (US) | 1995-01-03 | — | — | US | disclosed |
| US-5240923-A | Treating glaucoma | ALCON LABORATORIES, INC. (US) | 1993-08-31 | — | — | US | disclosed |
| EP-0527801-A4 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | — | 1993-03-10 | — | — | EP | disclosed |
| EP-0527801-A1 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | ALCON LABORATORIES, INC. (US) | 1993-02-24 | — | — | EP | disclosed |
| US-5153192-A | For controlling intraocular pressure | ALCON LABORATORIES, INC. (US) | 1992-10-06 | — | — | US | disclosed |
| WO-1991015486-A1 | THIOPHENE SULFONAMIDES USEFUL AS CARBONIC ANYDRASE INHIBITORS | ALCON LABORATORIES, INC. (US) | 1991-10-17 | — | — | WO | disclosed |
| US-4756742-A | Herbicides | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1988-07-12 | — | — | US | disclosed |
| CN-85101667-A | The aminosulfonylthiophene compound that replaces and the preparation method of its esters and as the purposes of weedicide | — | 1987-01-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024498-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | PRLHR, DRD2, AVPR2 | CYP2D6 556/4885CYP2C9 1930/4885CYP2C19 719/4885 |
| US-20140249137-A1 | PYRIMIDINE COMPOUNDS AS TUBERCULOSIS INHIBITORS | TYMS, TYMP, DPYD | CYP2D6 862/4885CYP2C9 1789/4885CYP2C19 1903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.